sacituzumab govitecan
gilead sciences
['tropics-02']
tropics-02 phase3 trial first results #asco22 question below 
CSO @RevealGenomics, TranslGenomics @IDIBAPS, Prof @UniBarcelona, Chair @_SOLTI, Team @IOBoncologia, COI https://t.co/HZFOVJKZcd